Latest Articles about SHPG

Shire Beats Earnings in 1Q - Analyst Blog

Zacks Equity Research — Fri, 03 May 2013 21:32:58 Z

Shire's ( SHPG ) first quarter 2013 earnings (excluding special items) of 1.63 as per American Depositary Share (ADS) beats the Zacks Consensus Estimate of $1.61. The reported quarter's

Earnings Plummet, Outlook Maintained at Sanofi - Analyst Blog

Zacks Equity Research — Fri, 03 May 2013 21:30:01 Z

Sanofi ( SNY ) reported first quarter 2013 business earnings of 81 cents per American Depository Share (ADS), below the Zacks Consensus Estimate of 89 cents. Earnings were down 29.0% at

Shire Settles Lawsuit with Actavis - Analyst Blog

Zacks Equity Research — Wed, 01 May 2013 21:48:50 Z

Shire ( SHPG ) recently announced that the company settled its pending litigation with Actavis, Inc ( ACT ), formerly known as Watson Pharmaceuticals. The litigation was primarily

Pre-Market Most Active for Apr 22, 2013 : PWER, NOK, ZNGA, SNY, BAC, CAT, GE, STM, SHPG, SIRI, QQQ, AAPL

NASDAQ.com News — Mon, 22 Apr 2013 16:39:57 Z

The NASDAQ 100 Pre-Market Indicator is up 6.63 to 2,787.09. The total Pre-Market volume is currently 15,778,718 shares traded. The following are the most active stocks for the pre-market

Positive Data on BioLineRx Treatment - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 03:12:18 Z

BioLineRx Ltd. ( BLRX ) recently announced encouraging results from a phase IIa study on BL-7040. BioLineRx is developing BL-7040 for the treatment of inflammatory bowel disease (IBD).

Cytokinetics Begins CK-2127107 Study - Analyst Blog

Zacks Equity Research — Sat, 06 Apr 2013 01:08:28 Z

Cytokinetics Inc. ( CYTK ) recently initiated a phase I study of CK-2127107 in healthy male volunteers. Cytokinetics is evaluating CK-2127107 for the potential improvement of the functions

Update on Protalix Gaucher Study - Analyst Blog

Zacks Equity Research — Fri, 05 Apr 2013 01:10:32 Z

Protalix BioTherapeutics, Inc. ( PLX ) recently announced the treatment of the first patient in a phase I study of PRX-112 or oral glucocerebrosidase enzyme (GCD). Oral GCD is being

Pernix Reports Loss in 4Q - Analyst Blog

Zacks Equity Research — Thu, 21 Mar 2013 22:33:16 Z

Pernix Therapeutics Holdings, Inc ( PTX ) posted a loss of 2 cents per share in the fourth quarter of 2012 compared to earnings of 15 cents per share in the year-ago quarter. The

Brazil Approves Pfizer-Protalix Gaucher Drug - Analyst Blog

Zacks Equity Research — Thu, 21 Mar 2013 18:33:19 Z

Pfizer Inc. ( PFE ) and Protalix BioTherapeutics, Inc. ( PLX ) recently announced the approval of their Gaucher drug, Uplyso (taliglucerase alfa), in Brazil. Uplyso has gained approval

Positive Results on AMAG's Feraheme - Analyst Blog

Zacks Equity Research — Tue, 19 Mar 2013 02:47:01 Z

AMAG Pharmaceuticals Inc. ( AMAG ) recently announced positive preliminary results from the IDA-303 study on Feraheme (ferumoxytol). The IDA-303 study evaluated the safety and efficacy of

Data on Abbott's MitraClip - Analyst Blog

Zacks Equity Research — Fri, 15 Mar 2013 20:46:30 Z

Abbott ( ABT ) recently released positive data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort. The study evaluated Abbott's MitraClip system

Shire Buys Premacure - Analyst Blog

Zacks Equity Research — Fri, 15 Mar 2013 02:49:15 Z

Shire plc ( SHPG ) recently announced that the company acquired privately held Premacure AB. Financial terms of the deal include an upfront payment along with milestone payments to

Corcept's Loss Narrows in 4Q - Analyst Blog

Zacks Equity Research — Thu, 14 Mar 2013 22:12:53 Z

Corcept Therapeutics Inc. ( CORT ) posted a loss per share of 11 cents in the fourth quarter of 2012 which was narrower than the loss of 12 cents posted in the year-ago quarter Adjusted

Simcere Gets Buyout Proposal - Analyst Blog

Zacks Equity Research — Thu, 14 Mar 2013 01:10:58 Z

China-based Simcere Pharmaceutical Group ( SCR ) recently announced that the company's board has received a buyout proposal from Mr. Jinsheng Ren, New Good Management Limited, Assure Ahead

FDA Approves Roche's New HCV Test - Analyst Blog

Zacks Equity Research — Wed, 13 Mar 2013 01:09:01 Z

Roche ( RHHBY ) recently announced that it has received approval from the US Food and Drug Administration (FDA) for a next-generation viral load test. The test uses a novel dual-probe